Back to Top Skip to main content

Navy Medicine researchers kick off 2019 Military Health System Research Symposium with strong showing

Navy Medicine West Commander Rear Adm. Tim Weber (right) discusses research findings with scientists from Navy Medicine's hospitals and research labs during the first poster session at the 2019 Military Health System Research Symposium. (U.S. Navy photo By Regena Kowitz) Navy Medicine West Commander Rear Adm. Tim Weber (right) discusses research findings with scientists from Navy Medicine's hospitals and research labs during the first poster session at the 2019 Military Health System Research Symposium. (U.S. Navy photo By Regena Kowitz)

Recommended Content:

MHSRS 2019 | Research and Innovation

KISSIMMEE, Fla. — Navy Medicine researchers from across the globe convened Aug. 19 in for the start of the 2019 Military Health System Research Symposium to discuss the latest scientific advances and initiatives that support warfighter health, readiness and survivability.

MHSRS is the Department of Defense’s annual, four-day scientific meeting that provides a venue for presenting new scientific knowledge resulting from military research and development.

“This is really one of the best meetings that we have in the MHS that brings together techniques, research projects, and capabilities to the warfighter,” said Navy Rear Admiral Bruce Gillingham, director, Medical Resources, Plans and Policy, Office of the Chief of Naval Operations. “It’s terrific to be here to support the work as we continue to focus on readiness for the Fleet and Marine Corps.”

This year, dozens of scientists from Navy military treatment facilities and medical research labs are presenting their work at two plenary sessions, speaking at more than 50 breakout sessions, and sharing more than 130 posters on research topics that include:

  • Surgical telementorship
  • Naval aviation survival training
  • Influenza vaccine effectiveness
  • Delayed amputation and limb salvage
  • Cognitive rehabilitation for the warfighter
  • Search and rescue patient transportation
  • Embedded mental health in operational settings

“This year, the real focus is on research for readiness,” said Navy Rear Admiral Darin Via, deputy chief of medical operations, Bureau of Medicine and Surgery. “That’s looking at how we support the warfighter, from mental health conditions and infectious disease, to blood support, advanced surgical techniques and increasing survivability on the battlefield. It’s great to see Navy Medicine represented so well in a joint environment.”

Navy Capt. Adam Armstrong, Naval Medical Research Center commander, was on hand to support scientists from the eight medical research laboratories that conduct studies aimed at enhancing readiness and increasing the well-being of future forces. These labs are situated in locations around the world – from Singapore to Dayton, Ohio – where they focus on emerging infectious diseases, combat casualty care, injury prevention and rehabilitation, aerospace and undersea medicine, and more.

“One of the great things about MHSRS is that we can bring all of our eight labs and show how we have the ability to do a wide range of research in the Navy,” Armstrong said. “One of the major things we’re doing is bringing innovation, knowledge, and products to the warfighter to keep them in the fight and get them back into the fight.”

To learn more about MHSRS 2019, check out the Military Health System or the MHSRS website.

Navy Medicine West (NMW) leads Navy Medicine’s Western Pacific health care system and global research and development enterprise. Throughout the region, NMW provides medical care to nearly 700,000 beneficiaries across 10 naval hospitals, two dental battalions, and 51 branch clinics located throughout the West Coast of the U.S., Asia, and the Pacific. Globally, NMW oversees eight research laboratories that deliver research expertise in support of warfighter health and readiness.

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

DHA-PI 3200.01: Research and Development (R&D) Enterprise Activity (EA)

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): a. Establishes the Defense Health Agency’s (DHA) procedures for the Deputy Assistant Director (DAD), R&D to manage and execute, on behalf of the Assistant Secretary of Defense for Health Affairs (ASD(HA)), the portion of the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation assigned to it (referred to as the “DHP Science and Technology (S&T) Program)”. The DHP S&T Program includes Budget Activities (BAs) 6.1-6.3 and 6.6. The ASD(HA) provides policy, direction, and guidance to inform planning, programming, budgeting, and execution of the DHP RDT&E appropriation in accordance with statute, regulation, and policy in Reference (a). The DAD-R&D, and Component Acquisition Executive (CAE) manage and execute DHP RDT&E Program funds aligned to them on behalf of the ASD(HA). The CAE is responsible for managing BAs 6.4, 6.5, and 6.7 funding, as well as Procurement and Operations and Maintenance funding required to support DHP-funded Acquisition Programs, regardless of acquisition activity. b. Supports the Director, DHA, in developing appropriate DHA management models to maximize efficiencies in the management and execution of DHP RDT&E-funded activities carried out by the Combatant Commands (CCMDs), Services, Uniformed Services University of the Health Sciences (USU), Defense Agencies, and other DoD Components, as applicable. c. Codifies processes to confirm DHP RDT&E funds are applied towards medical priorities and aligned to ASD(HA) policy, direction, and guidance to develop and deliver innovative medical products and solutions that increase the readiness of the DoD medical mission in accordance with Reference (a). d. Supports the following objectives of the R&D EA: (1) Increasing the quantity, quality, and pace of medical research through improved programmatic organization, processes, and oversight. (2) Ensuring DHP RDT&E funded efforts align to ASD(HA) published program guidance that provides resourcing guidance and translates national, departmental, and Service priorities into specific program objectives. (3) Verifying alignment of DHP RDT&E funds to medical priorities and to ASD(HA) policy, direction, and guidance to ensure the development and delivery of medical materiel and knowledge solutions. (4) Facilitating coordination with the CCMDs, Services, USU, Defense Agencies, and other DoD Components, as applicable, to ensure DHP RDT&E funded activities address joint medical capability gaps, and avoid unnecessary duplication.

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program

Policy

This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

<< < 1 > >> 
Showing results 1 - 2 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.